STLN (NASDAQ: STLN) revenue
STLN reported revenue of $502.7m for fiscal 2025, 27.8% more than in fiscal 2024 ($393.4m). Since fiscal 2020 its revenue has grown by 168.1%, an average growth of 21.8% a year.
STLN has grown its revenue for 5 years in a row, and fiscal 2025 is the highest of its 6 fiscal years on record.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $502.7m | +27.8% | −$36.1m | −7.2% |
| 2024 | $393.4m | +21.3% | −$60.1m | −15.3% |
| 2023 | $324.2m | +28.4% | −$77.0m | −23.8% |
| 2022 | $252.5m | +24.4% | −$82.0m | −32.5% |
| 2021 | $203.0m | +8.3% | −$45.9m | −22.6% |
| 2020 | $187.5m | — | −$8.2m | −4.4% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
STLN revenue compared with its sector
By revenue for its latest fiscal year, STLN ranks 193rd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; STLN, 27.8%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 191st | ADMA Biologics | $510.2m | 19.6% |
| 192nd | Glaukos | $507.4m | 32.3% |
| 193rd | STLN | $502.7m | 27.8% |
| 194th | BridgeBio Pharma | $502.1m | 126.3% |
| 195th | Travere Therapeutics | $490.7m | 110.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of STLN
- How much revenue did STLN make in fiscal 2025?
- STLN reported revenue of $502.7m for fiscal 2025, compared with $393.4m in fiscal 2024.
- How much has the revenue of STLN grown?
- Between fiscal 2020 and fiscal 2025 it went from $187.5m to $502.7m: 168.1% more, an average growth of 21.8% a year.
- What was the best year for revenue at STLN?
- Of its last 6 fiscal years, fiscal 2025, with $502.7m.
- Where does STLN rank in its sector by revenue?
- It ranks 193rd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for STLN come from?
- From the annual report (Form 10-K) that STLN files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that STLN files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on STLN: the STLN page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.